This site is intended for healthcare professionals

Results from Imbruvica RESONATE-2 study provide up to seven years of progression-free and overall survival data in first-line chronic lymphocytic leukemia. AbbVie

Read time: 1 mins
Last updated:9th Jun 2021
Published:9th Jun 2021
AbbVie announced extended long-term data from the Phase III RESONATE-2 study (PCYC-1115/1116) evaluating single-agent Imbruvica (ibrutinib) versus chlorambucil with up to seven years of follow-up in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL).
Condition: CLL/SLL
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest